Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 10/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118188 | 0.83 | MAP2K1 (0.39) | MAP2K1MAP2K2CREBBPATAD2ALOX15 | |
| SCHEMBL21475934 | 0.76 | MAP2K2 (0.39) | MAP2K1MAP2K2CREBBPATAD2BAZ2B | |
| SCHEMBL2116180 | 0.76 | BRD4 (0.36) | MAP2K1MAP2K2CREBBPATAD2BAZ2B | |
| SCHEMBL15549616 | 0.75 | ALKBH5 (0.37) | MAP2K1MAP2K2ATAD2 | |
| SCHEMBL20157938 | 0.74 | CREBBP (0.35) | MAP2K1MAP2K2CREBBPATAD2BAZ2B | |
| SCHEMBL24837083 | 0.74 | ATAD2 (0.35) | MAP2K1MAP2K2ATAD2BAZ2BBAZ2A | |
| SCHEMBL15550000 | 0.74 | BAZ2B (0.45) | MAP2K1MAP2K2CREBBPATAD2BAZ2B | |
| SCHEMBL21904988 | 0.74 | ATAD2 (0.35) | MAP2K1MAP2K2ATAD2ALOX15BAZ2B | |
| SCHEMBL22980995 | 0.74 | HDAC6 (0.33) | MAP2K1MAP2K2ATAD2 | |
| SCHEMBL24196391 | 0.74 | MAP2K2 (0.40) | MAP2K1MAP2K2TSHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2024246522-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | LARIO THERAPEUTICS LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| CN-114014842-B | Heterocyclic ketone compound and composition thereof, and preparation method and application thereof | 中国药科大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20230101559-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114014842-A | Heterocyclic ketone compound and composition thereof as well as preparation method and application thereof | 中国药科大学 | 2022-02-08 | — | — | CN | disclosed |
| US-20210253551-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3825313-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3800182-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210047304-A1 | Bromodomain Inhibitors | ABBVIE INC. | 2021-02-18 | — | — | US | disclosed |
| CN-111819181-A | Benzo-seven-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof | 罗欣药业(上海)有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200048220-A1 | Bromodomain Inhibitors | ABBVIE INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2019214399-A1 | BENZO- SEVEN-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | 罗欣药业(上海)有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019214399-A1 | BENZO- SEVEN-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | 罗欣药业(上海)有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| EP-3539960-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018086605-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047304-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | MAP2K1 1683/4885MAP2K2 1138/4885CREBBP 135/4885 |
| US-20210253551-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | MAP2K1 1843/4885MAP2K2 1214/4885CREBBP 129/4885 |
| US-20190284192-A1 | NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | MYC, BRD1, BRD3 | MAP2K1 1115/4885MAP2K2 1219/4885CREBBP 47/4885 |
| US-20200048220-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | MAP2K1 1655/4885MAP2K2 1167/4885CREBBP 111/4885 |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAP2K1 1843/4885MAP2K2 1214/4885CREBBP 129/4885 |
| US-20230101559-A1 | Bromodomain Inhibitors | BRD4, BRD3, BRD1 | MAP2K1 1843/4885MAP2K2 1214/4885CREBBP 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.